Banque Transatlantique SA Decreases Position in Zoetis Inc. $ZTS

Banque Transatlantique SA trimmed its stake in Zoetis Inc. (NYSE:ZTS) by 2.9% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 239,705 shares of the company’s stock after selling 7,172 shares during the period. Zoetis makes up about 0.9% of Banque Transatlantique SA’s portfolio, making the stock its 23rd biggest position. Banque Transatlantique SA owned about 0.05% of Zoetis worth $35,031,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently modified their holdings of ZTS. Brighton Jones LLC boosted its stake in Zoetis by 180.4% during the fourth quarter. Brighton Jones LLC now owns 4,629 shares of the company’s stock worth $754,000 after buying an additional 2,978 shares during the period. Empowered Funds LLC boosted its stake in shares of Zoetis by 6.2% during the 1st quarter. Empowered Funds LLC now owns 11,293 shares of the company’s stock worth $1,859,000 after purchasing an additional 657 shares during the period. Intech Investment Management LLC lifted its stake in Zoetis by 17.2% in the first quarter. Intech Investment Management LLC now owns 8,347 shares of the company’s stock worth $1,374,000 after purchasing an additional 1,224 shares during the last quarter. Sivia Capital Partners LLC lifted its stake in shares of Zoetis by 73.8% during the 2nd quarter. Sivia Capital Partners LLC now owns 3,348 shares of the company’s stock worth $522,000 after acquiring an additional 1,422 shares during the last quarter. Finally, Campbell & CO Investment Adviser LLC purchased a new position in Zoetis during the 2nd quarter valued at $814,000. Institutional investors own 92.80% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently commented on ZTS shares. Stifel Nicolaus cut their price target on shares of Zoetis from $140.00 to $130.00 and set a “hold” rating on the stock in a report on Tuesday, November 18th. William Blair reaffirmed an “outperform” rating on shares of Zoetis in a research report on Monday, March 2nd. The Goldman Sachs Group raised shares of Zoetis to a “buy” rating in a research report on Monday, December 15th. Barclays began coverage on shares of Zoetis in a report on Monday, December 8th. They issued an “equal weight” rating and a $136.00 price target on the stock. Finally, Bank of America boosted their price objective on shares of Zoetis from $135.00 to $140.00 and gave the stock a “neutral” rating in a research note on Friday, February 13th. Six investment analysts have rated the stock with a Buy rating and eight have given a Hold rating to the stock. According to data from MarketBeat.com, Zoetis currently has an average rating of “Hold” and a consensus price target of $152.91.

Zoetis Price Performance

Zoetis stock opened at $115.62 on Friday. The company has a fifty day simple moving average of $125.34 and a 200-day simple moving average of $131.91. The company has a quick ratio of 1.94, a current ratio of 3.03 and a debt-to-equity ratio of 2.71. The firm has a market capitalization of $48.81 billion, a price-to-earnings ratio of 19.21, a PEG ratio of 1.76 and a beta of 0.95. Zoetis Inc. has a 52-week low of $114.47 and a 52-week high of $172.23.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, February 12th. The company reported $1.48 earnings per share for the quarter, topping analysts’ consensus estimates of $1.40 by $0.08. The firm had revenue of $2.39 billion for the quarter, compared to analyst estimates of $2.36 billion. Zoetis had a net margin of 28.24% and a return on equity of 62.02%. Zoetis’s quarterly revenue was up 3.0% on a year-over-year basis. During the same period in the previous year, the business posted $1.40 earnings per share. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. On average, equities analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 2nd. Shareholders of record on Monday, April 20th will be issued a $0.53 dividend. This represents a $2.12 annualized dividend and a yield of 1.8%. The ex-dividend date is Monday, April 20th. Zoetis’s dividend payout ratio is presently 35.22%.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.